| Document |
Document Title |
|
WO/2014/021281A1 |
Provided is a compound which is represented by general formula (I') and has an excellent PHD2-inhibiting activity or a pharmaceutically acceptable salt thereof. (In the general formula (I'), W, Y, R2, R3, R4 and Y4 are as defined in the ...
|
|
WO/2014/022528A1 |
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated b...
|
|
WO/2014/016314A1 |
A compound having the formula (I), for use in treating a disease; a composition comprising said fused quinonic compound of formula (I) and at least one pharmaceutically acceptable carrier; as well as a method of modulating a Janus Kinase...
|
|
WO/2014/017042A1 |
[Problem] To manufacture, in a stable manner, an organic photoelectric conversion element having an equivalent performance, and an imaging element provided with the same. [Solution] A film-forming organic material (60) used for dry film-...
|
|
WO/2014/012964A1 |
It relates to spirocyclic compounds of formula (I),or pharmaceutically or veterinary acceptable salts thereof, or any stereoisomers either of the compounds of formula (I) or of their pharmaceutically or veterinary acceptable salts, where...
|
|
WO/2014/013507A1 |
Disclosed herein is a tunable fluorescent polymer composition comprising silk and one or more polymerizable monomer provided with fluorescent probe, wherein, the said one or more polymerizable monomer provided with fluorescent probe is g...
|
|
WO/2013/182263A1 |
The invention relates to specific phenanthrenes, the use of the compound in an electronic device, and an electronic device containing at least one of said compounds. The invention further relates to a method for producing the compound an...
|
|
WO/2013/174736A1 |
The present application relates to novel substituted 2-(piperidin-1- yl)acetamide derivatives of the formula (I) in which A is an optionally substituted or fused piperidine ring of the formula (I‑a) or (I‑b), to processes for prepara...
|
|
WO/2013/167963A1 |
The present invention is directed to Benzomorphan Analog compounds of the Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (ID) as shown below, wherein R1, R2a, R2b, R3, R4, Z, and G are as defined herein. Compounds of t...
|
|
WO/2013/167711A1 |
The compounds of formula (I), or its pharmaceutically acceptable salts, or any stereoisomer or mixture thereof, wherein: R1 is a (C1-C2) alkyl radical; R2 and R3 are radicals independently selected from the group consisting of F, CI and ...
|
|
WO/2013/163668A1 |
The present invention relates to genetically modified plants of the species Papaver bracteatum wherein the type or amount of one or more alkaloids produced by the plants has been modified. Specifically, the genetically modified plants ha...
|
|
WO/2013/156423A1 |
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, A and n are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2013/149997A1 |
The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for ...
|
|
WO/2013/148537A1 |
The present invention provides spirobicyclic compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, diff...
|
|
WO/2013/139195A1 |
Disclosed in the present invention is a Huperzine A polycrystal, preparation method therefor, a pharmaceutical composition comprising the polycrystal and the use thereof. Part of the Huperzine A polycrystal has a better solubility than t...
|
|
WO/2013/139006A1 |
Disclosed are an anthrapyridone fluorescent dye N-substituted in position 4, the preparation method and use thereof, the compound having a structure as shown in general formula I. In general formula I, n is an integer of 1-10; R is selec...
|
|
WO/2013/133218A1 |
The objective of the present invention is to provide a photoelectric conversion element provided with a photoelectric conversion film that can even be produced by means of a continuous vapor deposition process under high temperature cond...
|
|
WO/2013/125688A1 |
The invention relates to an organocatalyst for oxidizing alcohols; a primary alcohol is selectively oxidized in a polyol substrate having a plurality of alcohols under environmentally-friendly conditions. The organic oxidation catalyst f...
|
|
WO/2013/118118A1 |
The present invention relates to novel alpha-hydrogen substituted nitroxyl compounds and their corresponding oxidized (oxoammonium cations) and reduced (hydroxylamine) forms, and to the use of such compounds, inter alia, for (1) oxidatio...
|
|
WO/2013/091539A1 |
The present invention relates to a pyrrole six-membered heteroaryl ring derivative, the preparation method therefor, and the medicinal uses thereof. Specifically, the present invention relates to a new pyrrole six-membered heteroaryl rin...
|
|
WO/2013/084013A1 |
The present invention relates to compounds of formula 1 that are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases caused by abnormal activation of CXCR3 chemokines. The invention rela...
|
|
WO/2013/083216A1 |
The present invention relates to compounds of formulae (1), (2) or (3) that are suitable for use in electronic devices, and to electronic device, in particular organic electroluminescence devices, containing these compounds.
|
|
WO/2013/068275A1 |
The invention concerns a polymer-bonded polycyclic aromatic hydrocarbon compound of general formula (1): (P—O) x —Q—(Y) w (1) wherein P represents a polymeric moiety having at least three repeating units which comprise an optionall...
|
|
WO/2013/060258A1 |
The present invention relates to 3 alkaloids (clavatine A-C) isolated from Lycopodium japonicum Thunb., a pharmaccodynamically acceptable salt thereof and a preparation method thereof, a pharmaceutical composition containing this class o...
|
|
WO/2013/057320A1 |
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a n...
|
|
WO/2013/051724A1 |
An object of the present invention is to provide a water-insoluble coloring matter compound having high solubility for a solvent and high lightness and chroma and providing a chromaticity closer to the magenta chromaticity represented by...
|
|
WO/2013/044596A1 |
Disclosed in the present invention are a compound and a pharmaceutical composition used for inhibiting the activity of a kidney-type glutaminase, and the use of the compound in treatment, especially in treating or preventing diseases, in...
|
|
WO/2013/042035A1 |
The present invention relates to novel heterocyclic compounds which specifically inhibit bacterial Fab I and can be used for the treatment of Staphylococcal infections.
|
|
WO/2013/010218A9 |
Inhibitors are provided for inhibiting the activity of clathrin. In particular, binding site(s) on the clathrin terminal doman (TD) for binding inhibitors have been identified. The binding sites are defined by amino acid(s) in the group ...
|
|
WO/2013/030111A1 |
The invention relates to compounds that can be used in particular as structural mimetics of proline-rich peptides and accordingly are able to bind PRM (proline-rich motif) binding domains of proteins. The invention further relates to the...
|
|
WO/2013/029260A1 |
The present invention relates to a class of compounds as represented by general formula (I) or (III), or salt thereof, or mixture thereof, and a preparation method and use thereof. In formula (I), X1 is H or CO2H; X2 is OH or a phenyl wi...
|
|
WO/2013/026947A1 |
The invention relates to compounds formed by a small molecule that can bind to double-stranded DNA, covalently linked to a photolabile protecting group, and to the uses thereof. The deprotection of these compounds by means of light irrad...
|
|
WO/2013/028999A1 |
The invention provides a compound having the structure (I), wherein A is a substituted or unsubstituted ring; Z is present or absent and when present is (II), wherein n is 0, 1, 2, 3, or 4; Y is -(CR11R12)-, -NH(CR11R12)- or -O(CR11R12)-...
|
|
WO/2013/024026A1 |
The present invention provides a compound of formula (1). The compound of formula (1) is suitable for use as semiconducting material, in particular in electronic devices.
|
|
WO/2013/025664A1 |
Disclosed is a compound of formula I and salts thereof. Also disclosed are methods of making the compound of formula (I) and the use of the compound as an intermediate for making pharmaceutically active compounds such as 11- -hydroxyster...
|
|
WO/2013/024730A1 |
This organic electroluminescent element, which uses a compound represented by the belowmentioned general formula, emits dark blue light and has a low change in chromaticity and a low change in driving voltage after long-term driving. (R1...
|
|
WO/2013/013505A1 |
The present invention relates to a 9-aminomethyl substituted tetracycline compound represented by general formula (I), pharmaceutically acceptable salts, solvates or isomers thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7, R8, ...
|
|
WO/2013/013504A1 |
The invention belongs to the medicinal technical field, and in particular relates to a tigecycline derivative of general formula (I), a pharmaceutically acceptable salt, precursor drug, solvate or isomer thereof, wherein R2a, R2b, R3, R4...
|
|
WO/2013/004290A1 |
There is described a novel group of cyclic amine derivative compounds, having an EP4 receptor antagonistic activity and specifically pharmaceutical compounds which are useful for the treatment or alleviation of Prostaglandin E mediated d...
|
|
WO/2012/175962A1 |
Provided are compounds for use in a method of treatment of a subject who has a lesion or a tumour in which p53 carries a Y220C mutation, in which the compound is selected from compounds of the following formula (I), and pharmaceutically ...
|
|
WO/2012/160182A1 |
The invention provides a method of increasing the solubility and/or dispersibility of a quaterrylene and/or terrylene dye in a liquid medium such as, e.g., a liquid medium comprised in a printing ink composition. The method comprises cov...
|
|
WO/2012/159213A1 |
There are provided compounds comprising optionally substituted (FORMULA I) fused with one or two optionally substituted (FORMULA II), wherein A and E each independently represent -CH 2 -, -NH-, -O-, -S-, or -C(=O)- and B represents a bon...
|
|
WO/2012/149113A1 |
Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action mu-opioid receptor antagonist/kappa-opioid receptor agonist or prodrug thereof to a subject in need thereof, sufficient t...
|
|
WO/2012/145981A1 |
Chain compounds containing Adamantane or adamantane-like group, its stereoisomers, prodrugs, pharmaceutical salts, complex salt and solvate are provided. It comprises formula (I), where in S is a optionally substituted cyclic group, P is...
|
|
WO/2012/147330A1 |
[Problem] To provide an organic compound, as a material for a highly efficient and highly durable organic electroluminescent element, which exhibits excellent hole injection and transportation capabilities and has electron stopping abili...
|
|
WO/2012/143661A1 |
The present invention relates to a method for quantifying living bacteria in a liquid medium likely to contain same, characterised in that the following consecutive steps are performed: 1) yeast is added to said sample and mixing is carr...
|
|
WO/2012/141249A1 |
An organic electroluminescent element using a compound represented by general formula (AA) has high luminous efficiency and excellent color purity, while being suppressed in chromaticity change due to driving deterioration. (In the formu...
|
|
WO/2012/125871A2 |
Compound derivatives of aconitine are provided, in particular derivatives that modulate the activity of sodium channels. Also provided are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptabl...
|
|
WO/2012/122101A1 |
Methods for increasing the amount of calcium in the cytoplasm and the mitochondria of a cancer cell expressing the G Protein-Coupled Estrogen Receptor GPR30 comprise agonizing the GPR30. In some aspects, the methods further comprise inhi...
|
|
WO/2012/121863A1 |
The invention provides (1) processes for making substantially-pure (-) huperzine A and substantially-pure (-) huperzine A derivatives; (2) compositions useful in making substantially-pure (-) huperzine A and substantially-pure (-) huperz...
|
